echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Chinese scientists have made important progress in the development of new rapid antidepressant drugs

    Chinese scientists have made important progress in the development of new rapid antidepressant drugs

    • Last Update: 2021-08-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medical Network News on August 2nd, Chinese scientists have made important progress in the development of new antidepressants
    .
    On the 28th, the journal Nature published an online research paper titled "Structural Basis of Ketamine Acting on Human NMDA Receptors"
    .
    The study, completed by Shujia Zhu's research group in the Center for Excellence in Brain Science and Intelligent Technology Innovation of the Chinese Academy of Sciences, and Luo Cheng's research group at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, has important guiding significance for the development of new fast, efficient, and low-side-effect antidepressants
    .
     
    According to Zhu Shujia, depression is not a simple psychological problem, but a pathological change in the brain
    .
    NMDA receptors are the most important excitatory ion channels in the brain and are the molecular switches for learning and memory
    .
    Depression is related to the dysfunction of NMDA receptors in the brain
    .
     
    Ketamine is an important discovery in the field of antidepressants in recent decades.
    It can act as a blocker of NMDA receptors in the brain, participate in the regulation of brain signaling pathways, and repair brain synaptic damage caused by chronic stress
    .
    After the medication, within a few hours, it can improve the patient's depression, low self-evaluation and other negative symptoms, reduce the patient's suicidal ideation, and have a therapeutic effect on refractory depression
    .
    However, ketamine can cause side effects such as dissociative hallucinations, which greatly limits its clinical application
    .
     
    Since 2006, Zhu Shujia has been devoted to studying the mechanism of NMDA receptors
    .
    After entering the Center for Excellence in Brain Science and Intelligent Technology of the Chinese Academy of Sciences, she led the team to systematically explain how the activity of NMDA receptors is regulated by ligands and various small molecules, which greatly promoted people's scientific understanding of the working mechanism of NMDA receptors
    .

     
      In the latest research, Zhu Shujia's team combined advanced cryo-electron microscopy technology to analyze the binding site of ketamine on the NMDA receptor and reveal its molecular mechanism of action
    .
    This series of basic scientific research breakthroughs not only provide a strong theoretical basis for the design of safer and more effective antidepressants, but also bring new opportunities for the subsequent realization of personalized precision medicine
    .

      Medical Network News on August 2nd, Chinese scientists have made important progress in the development of new antidepressants
    .
    On the 28th, the journal Nature published an online research paper titled "Structural Basis of Ketamine Acting on Human NMDA Receptors"
    .
    The study, completed by Shujia Zhu's research group in the Center for Excellence in Brain Science and Intelligent Technology Innovation of the Chinese Academy of Sciences, and Luo Cheng's research group at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, has important guiding significance for the development of new fast, efficient, and low-side-effect antidepressants
    .
     
      According to Zhu Shujia, depression is not a simple psychological problem, but a pathological change in the brain
    .
    NMDA receptors are the most important excitatory ion channels in the brain and are the molecular switches for learning and memory
    .
    Depression is related to the dysfunction of NMDA receptors in the brain
    .
     
      Ketamine is an important discovery in the field of antidepressants in recent decades.
    It can act as a blocker of NMDA receptors in the brain, participate in the regulation of brain signaling pathways, and repair brain synaptic damage caused by chronic stress
    .
    After the medication, within a few hours, it can improve the patient's depression, low self-evaluation and other negative symptoms, reduce the patient's suicidal ideation, and have a therapeutic effect on refractory depression
    .
    However, ketamine can cause side effects such as dissociative hallucinations, which greatly limits its clinical application
    .
     
      Since 2006, Zhu Shujia has been devoted to studying the mechanism of NMDA receptors
    .
    After entering the Center for Excellence in Brain Science and Intelligent Technology of the Chinese Academy of Sciences, she led the team to systematically explain how the activity of NMDA receptors is regulated by ligands and various small molecules, which greatly promoted people's scientific understanding of the working mechanism of NMDA receptors
    .

     
      In the latest research, Zhu Shujia's team combined advanced cryo-electron microscopy technology to analyze the binding site of ketamine on the NMDA receptor and reveal its molecular mechanism of action
    .
    This series of basic scientific research breakthroughs not only provide a strong theoretical basis for the design of safer and more effective antidepressants, but also bring new opportunities for the subsequent realization of personalized precision medicine
    .

      Medical Network News on August 2nd, Chinese scientists have made important progress in the development of new antidepressants
    .
    On the 28th, the journal Nature published an online research paper titled "Structural Basis of Ketamine Acting on Human NMDA Receptors"
    .
    The study, completed by Shujia Zhu's research group in the Center for Excellence in Brain Science and Intelligent Technology Innovation of the Chinese Academy of Sciences, and Luo Cheng's research group at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, has important guiding significance for the development of new fast, efficient, and low-side-effect antidepressants
    .
     
      According to Zhu Shujia, depression is not a simple psychological problem, but a pathological change in the brain
    .
    NMDA receptors are the most important excitatory ion channels in the brain and are the molecular switches for learning and memory
    .
    Depression is related to the dysfunction of NMDA receptors in the brain
    .
    Mental mental mental
     
      Ketamine is an important discovery in the field of antidepressants in recent decades.
    It can act as a blocker of NMDA receptors in the brain, participate in the regulation of brain signaling pathways, and repair brain synaptic damage caused by chronic stress
    .
    After the medication, within a few hours, it can improve the patient's depression, low self-evaluation and other negative symptoms, reduce the patient's suicidal ideation, and have a therapeutic effect on refractory depression
    .
    However, ketamine can cause side effects such as dissociative hallucinations, which greatly limits its clinical application
    .
     
      Since 2006, Zhu Shujia has been devoted to studying the mechanism of NMDA receptors
    .
    After entering the Center for Excellence in Brain Science and Intelligent Technology of the Chinese Academy of Sciences, she led the team to systematically explain how the activity of NMDA receptors is regulated by ligands and various small molecules, which greatly promoted people's scientific understanding of the working mechanism of NMDA receptors
    .

     
      In the latest research, Zhu Shujia's team combined advanced cryo-electron microscopy technology to analyze the binding site of ketamine on the NMDA receptor and reveal its molecular mechanism of action
    .
    This series of basic scientific research breakthroughs not only provide a strong theoretical basis for the design of safer and more effective antidepressants, but also bring new opportunities for the subsequent realization of personalized precision medicine
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.